Combined Radiotherapy and Sorafenib in Patients With Hepatoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01319942|
Recruitment Status : Unknown
Verified March 2011 by China Medical University Hospital.
Recruitment status was: Recruiting
First Posted : March 22, 2011
Last Update Posted : March 22, 2011
|Condition or disease||Intervention/treatment|
|Hepatocellular Carcinoma||Other: Radiotherapy combined with sorafenib|
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients present with intermediate or advanced disease. Percutaneous ethanol injection, radiofrequency ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a curative treatment and have achieved very limited success in eradicating large HCC. With the development of new radiotherapy (RT) technique, RT can be more safely given to patients with larger tumor burden. Thus, TACE combined with RT has been suggested for treating large HCC. Based on the results of these studies, RT could achieve a tumor response rate of 50 % to 70 %. However, it has not been definitively shown to prolong the overall or disease-free survival due to lack of a phase III clinical trial. In contrast, a retrospective clinical investigation with molecular study suggests that sublethal dose of RT promoted HCC growth outside RT field.
Two phase III trials were shown to be efficacious and well-tolerated in patients with advanced HCC. Median overall survival was significantly 2 to 3 months longer in the sorafenib group than that in the placebo. It is interesting to recognize the combined therapeutic effect of RT with sorafenib. Based on several preclinical experiments, tumor angiogenesis inhibitors seem to be synergistic with irradiation when using before RT, concurrently with RT, or after RT. Thus, we design a single-arm phase II clinical trial to investigate the efficacy of combined RT with sorafenib.
The eligibility criteria are patients with unresectable HCC; good performance status; no prior radiotherapy for the liver; clinical measurable tumor; good liver function and good compliance. After entering this study, the testee will receive RT to hepatic tumor with concurrently sorafenib with a dose of 400 mg twice daily. Hepatic RT will be performed with a daily fraction size of 2.0 to 2.5 Gy to a total dose of 46 Gy to 60 Gy. After RT, maintenance sorafenib with a dose of 400 mg twice daily will be ongoing. Sorafenib will be continued until the occurrence of clinical or radiologic progression, or the occurrence of either unacceptable adverse events or death. Minimum maintenance duration of 6 months is recommended, but not mandatory. The primary end points are response rate and toxicities profile. The secondary endpoints are time to radiological progression interval (TRPI), overall survival, and quality of life assessment.
|Study Type :||Observational|
|Estimated Enrollment :||45 participants|
|Official Title:||Combined Radiotherapy and Sorafenib in Patients With Hepatoma|
|Study Start Date :||June 2010|
|Estimated Primary Completion Date :||June 2012|
|Estimated Study Completion Date :||June 2013|
Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
Other: Radiotherapy combined with sorafenib
Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
Other Name: Radiotherapy with sorafenib
- Response rate [ Time Frame: 1-month and 6-month response rate ]
- Response rate at 1-month and 6-month after radiotherapy.
- Toxicities profile of combinede treatment
- Time-to radiological progression interval [ Time Frame: 2-years ]
- Time-to radiological progression interval
- 2-year overall survival
- 2-year progression-free survival
- Quality of life
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01319942
|Contact: Shang-Wen Chen, MD||886-4-22052121 ext firstname.lastname@example.org|
|Tainan, Taiwan, 600|
|Contact: Li-Ching Lin, MD 886-6-2812811 ext 53501 email@example.com|
|Principal Investigator: Li-Ching Lin, MD|
|Taipei Medical University Hospital||Recruiting|
|Taipei, Taiwan, 100|
|Contact: Jeng-Fong Chiou, MD;PhD 886-2-27372181 ext 2130 firstname.lastname@example.org|
|Principal Investigator: Jen-Fong Chiou, MD;PhD|
|Principal Investigator:||Shang-Wen Chen, MD||Department of Radiation Oncology, China Medical University Hospital|